| |
| |
|
| Insider
Information: |
Aryeh Jason |
| Relationship: |
Director |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
401,047 |
|
|
Indirect Shares
|
890,847 |
|
|
| Direct
Value |
$7,148,144 |
|
|
|
Indirect Value
|
$4,945,268 |
|
|
| Total
Shares |
1,291,894 |
|
|
| Total
Value |
$12,093,412 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Ligand Pharmaceuticals Inc |
LGND |
Director |
2024-04-30 |
76,828 |
2024-04-30 |
56,619 |
Premium* |
|
|
Vaxart Inc |
VXRT |
Director |
2010-12-27 |
0 |
2011-03-15 |
131,783 |
Premium* |
|
|
Myrexis Inc |
MYRX |
Director |
|
0 |
2012-06-15 |
552,145 |
Premium* |
|
|
Novelion Therapeutics Inc |
NVLN |
Director |
2017-05-15 |
242,433 |
2017-05-15 |
150,300 |
Premium* |
|
|
Aralez Pharmaceuticals Inc. |
ARLZ |
Director |
2017-05-23 |
15,000 |
2017-05-23 |
0 |
Premium* |
|
|
Merrimack Pharmaceuticals Inc |
MACK |
See Explanation of Res... |
2019-07-16 |
3,802 |
2019-07-11 |
0 |
Premium* |
|
|
Orchestra BioMed Holdings Inc. |
OBIO |
Director |
2023-04-12 |
62,984 |
2023-01-26 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
175 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 4 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2007-05-30 |
4 |
B |
$6.48 |
$21,708 |
I/I |
3,350 |
12,150 |
2.1 |
- |
|
| VXRT |
Vaxart Inc |
Director |
– • – |
2011-03-14 |
4 |
S |
$5.82 |
$19,828 |
I/I |
(3,400) |
136,683 |
0 |
- |
|
| MACK |
Merrimack Pharmaceuticals... |
See Explanation of Responses |
– – • |
2019-07-12 |
4 |
B |
$5.62 |
$19,324 |
D/D |
3,400 |
3,500 |
2.37 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2018-02-23 |
4 |
S |
$155.00 |
$529,635 |
I/I |
(3,417) |
86,834 |
0 |
- |
|
| VXRT |
Vaxart Inc |
Director |
– • – |
2010-01-07 |
4 |
AS |
$5.29 |
$18,213 |
I/I |
(3,443) |
733,577 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2016-11-25 |
4 |
S |
$106.96 |
$372,007 |
I/I |
(3,478) |
185,898 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2011-03-14 |
4 |
B |
$9.59 |
$33,900 |
I/I |
3,500 |
271,111 |
2.1 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2018-03-08 |
4 |
S |
$174.88 |
$612,095 |
I/I |
(3,500) |
83,334 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2011-03-11 |
4 |
B |
$9.75 |
$39,355 |
I/I |
4,000 |
3,025 |
2.1 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2011-03-16 |
4 |
B |
$9.25 |
$37,405 |
I/I |
4,000 |
276,611 |
2.1 |
- |
|
| MYRX |
Myrexis Inc |
Director |
– • – |
2012-06-14 |
4 |
B |
$2.36 |
$9,450 |
I/I |
4,000 |
541,220 |
2.1 |
- |
|
| NVLN |
Novelion Therapeutics Inc |
Director |
– • – |
2014-12-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,000 |
4,000 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2018-03-09 |
4 |
S |
$176.47 |
$705,899 |
I/I |
(4,000) |
79,334 |
0 |
- |
|
| MYRX |
Myrexis Inc |
Director |
– • – |
2012-05-30 |
4 |
B |
$2.47 |
$9,909 |
I/I |
4,020 |
525,971 |
2.1 |
- |
|
| VXRT |
Vaxart Inc |
Director |
– • – |
2009-12-16 |
4 |
S |
$5.24 |
$21,196 |
I/I |
(4,045) |
787,420 |
0 |
- |
|
| VXRT |
Vaxart Inc |
Director |
– • – |
2010-10-11 |
4 |
S |
$5.00 |
$22,110 |
I/I |
(4,422) |
244,456 |
0 |
- |
|
| VXRT |
Vaxart Inc |
Director |
– • – |
2010-12-08 |
4 |
S |
$5.49 |
$25,830 |
I/I |
(4,705) |
181,783 |
0 |
- |
|
| VXRT |
Vaxart Inc |
Director |
– • – |
2010-11-11 |
4 |
S |
$5.30 |
$25,970 |
I/I |
(4,900) |
201,383 |
0 |
- |
|
| VXRT |
Vaxart Inc |
Director |
– • – |
2010-11-18 |
4 |
S |
$5.24 |
$25,676 |
I/I |
(4,900) |
196,483 |
0 |
- |
|
| VXRT |
Vaxart Inc |
Director |
– • – |
2011-03-15 |
4 |
S |
$5.87 |
$28,763 |
I/I |
(4,900) |
131,783 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2007-05-30 |
4 |
B |
$6.48 |
$32,400 |
D/D |
5,000 |
29,700 |
2.39 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2007-05-31 |
4/A |
A |
$0.00 |
$0 |
D/D |
5,000 |
34,700 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2008-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
39,700 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2009-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
44,700 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2010-06-01 |
4 |
B |
$1.48 |
$7,400 |
D/D |
5,000 |
86,574 |
2.39 |
- |
|
175 Records found
|
|
Page 4 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
